ICARE Newsletter Summer 2018

Another PARP-Inhibitor Trial Among BRCA Carriers with Advanced Breast Cancer

In a Phase 3 clinical trial among BRCA carriers with advanced breast cancer, an oral PARP Inhibitor (talazoparib) was compared to standard chemotherapy.  Among those who received the PARP inhibitor, risk of disease progression or death was 46% lower, and the response rate was double. Furthermore, the side effect profile, quality-of-life measures, and breast cancer symptoms were more favorable in the PARP inhibitor group. These findings indicate that talazoparib among this group of patients results in longer progression-free survival than standard chemotherapy, with better patient-reported outcomes.

Litton JK, et al.. N Engl J Med. 2018 Aug 15. PMID: 30110579.

Permanent link to this article: https://inheritedcancer.net/8nls2018/